Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.

Shinichi OkaVicki HolohanTakuma ShirasakaJun Yong ChoiYeon-Sook KimNadine ChamayParul PatelJoseph W PolliSusan L FordHerta CrauwelsLouise GarsideRonald D'AmicoChristine LathamRodica van Solingen-RisteaBryan BaughJean van Wyk

Published in: HIV medicine (2023)

CAB + RPV LA demonstrated high efficacy, with no participants having CVF, and an acceptable safety profile in Asian participants through week 96. These data support CAB + RPV LA as a complete regimen for the maintenance of HIV-1 virological suppression in Asian individuals.

Keyphrases

antiretroviral therapy
hiv infected
hiv infected patients
human immunodeficiency virus
hiv positive
hiv aids
hepatitis c virus
electronic health record
type diabetes
hiv testing
machine learning
big data
men who have sex with men
data analysis
insulin resistance